Trial · NCT07076121
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121, Phase 2, Phase 3, Active not recruiting, Bristol-Myers Squibb
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30). Trials, record NCT07076121. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07076121
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
- NCT number
- NCT07076121
- Status
- Active not recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 470 participants, estimated
- Lead sponsor
- Bristol-Myers Squibb
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Navlimetostat, Gemcitabine, Nab-paclitaxel, Placebo
- First posted
- 2025-07-21
- Last updated
- 2026-06-03
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-Free Survival as assessed by Response Evaluation Criteria in Solid Tumors version v1.1 (RECIST v1.1) | Up to 3 years after last participant is randomized | Defined as the time between the randomization date and the date of progressive disease (PD) or death from any cause (whichever occurs first) |
| Primary | Overall Survival (OS) | Up to 3 years after last participant is randomized | Defined as the time from the randomization date to the date of death from any cause |
| Secondary | Objective Response (OR) as assessed by RECIST v1.1 | Up to 3 years after last participant is randomized | |
| Secondary | Duration of Response (DOR) as assessed by RECIST v1.1 | Up to 3 years after last participant is randomized | Defined as the time between the date of the first documentation of objective tumor response (complete response (CR) or partial response (PR)) and the date of disease progression or to death from any cause (whichever occurs first) |
| Secondary | Time to Objective Response (TTOR) as assessed by RECIST v1.1 | Up to 3 years after last participant is randomized | Defined as the time between randomization to the date of the first documentation of objective tumor response |
| Secondary | Disease control as assessed by RECIST v1.1 | Up to 3 years after last participant is randomized | Defined as the best overall response (BOR) of confirmed CR, PR, or stable disease (SD) |
| Secondary | Number of participants with treatment-related adverse events (TRAEs) | Up to 28 days after the last drug administration | |
| Secondary | Number of participants with all-cause treatment-emergent adverse events (TEAEs) | Up to 28 days after the last drug administration | |
| Secondary | Number of participants with treatment-emergent serious adverse events (TESAEs) | Up to 28 days after the last drug administration | |
| Secondary | Number of participants with TEAEs leading to dose interruption, reduction, or discontinuation | Up to 28 days after the last drug administration |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07076121
GET https://conductscience.org/api/trials/v1/NCT07076121/registered